8-K: Veru Inc. Pivots Sabizabulin to Pancreatic Cancer

Veru Inc. announces a strategic shift to advance sabizabulin for drug-resistant pancreatic cancer, leveraging new preclinical data and pausing inflammation research.

Summary

• Veru Inc. is advancing its oral drug sabizabulin for patients with metastatic pancreatic cancer that has become resistant to daraxonrasib.
• This decision follows positive preclinical data showing sabizabulin's augmented anticancer activity against KRAS-mutant pancreatic cancer cell lines resistant to daraxonrasib.
• The company will no longer pursue sabizabulin for chronic inflammation related to atherosclerotic cardiovascular disease.
• Veru plans to initiate a Phase 2b clinical trial for this new indication.
• The company's enobosarm program for obesity is on track, with an interim analysis of the Phase 2b PLATEAU trial expected in Q1 2027.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, driven by promising preclinical data and a strategic pivot, though significant clinical and regulatory hurdles remain.

Positives

• Positive preclinical data demonstrates sabizabulin's potential to overcome resistance to daraxonrasib in pancreatic cancer cell lines.
• Sabizabulin showed potent anticancer activity (IC50=18.2nM) in resistant cell lines, a concentration achievable with current dosing and good safety.
• The company has strong intellectual property protection for sabizabulin until 2043.
• The enobosarm obesity program is on track, with a Phase 2b trial fully enrolled and a clinical supply agreement with Novo Nordisk in place.
• A new patent provides enobosarm IP protection with GLP-1 RA until late 2044.

Negatives

• The company is discontinuing research into sabizabulin for chronic inflammation related to atherosclerotic cardiovascular disease.
• Pancreatic cancer has a dismal survival rate, with resistance to therapies like daraxonrasib being a significant challenge.
• Advancement of sabizabulin beyond the pre-IND meeting is contingent on securing additional funding.

Risks

• The FDA may not agree with the proposed study designs for future clinical trials.
• Results from preclinical and prior clinical studies may not be predictive of future development or efficacy.
• There is a risk of delays in clinical trials due to patient enrollment challenges.
• The company may not be able to secure sufficient funding to advance the sabizabulin program.
• The supply agreement with Novo Nordisk could be terminated.
• Competition from other companies with greater resources exists.
• Potential for disruptions at the FDA or other government agencies.

Future Outlook

The company plans to advance sabizabulin into a Phase 2b clinical trial for metastatic pancreatic cancer resistant to daraxonrasib, following a pre-IND meeting with the FDA in Q4 2026. The enobosarm obesity program's Phase 2b PLATEAU trial interim analysis is expected in Q1 2027, with final topline data in Q4 2027.

Management Comments

• "The recent FDA approval of Revolution Medicines daraxonrasib was a major breakthrough in the treatment of KRAS-driven metastatic pancreatic cancer. Unfortunately, resistance to daraxonrasib occurs as the median time to cancer progression was 7.2 months in patients receiving daraxonrasib. The primary mechanism that leads to daraxonrasib reactivation is reactivation of the KRAS signaling pathway. As sabizabulin targets downstream components of the KRAS signaling pathway, we explored and confirmed in recently completed preclinical studies that sabizabulin has the potential to treat metastatic pancreatic cancer that has become resistant to daraxonrasib. This exciting new development and the importance of this large unmet medical need compel us to pursue this novel sabizabulin oncology indication. With the goal of maximizing Veru shareholder value, we have made the strategic decision to advance sabizabulin into a Phase 2b clinical trial. Consequently, we will no longer be exploring sabizabulin for the treatment of chronic inflammation related to atherosclerotic cardiovascular disease."
• "Our enobosarm obesity program is completely on track. The Phase 2b PLATEAU clinical trial is fully enrolled, and we expect the interim analysis, a near term milestone, in calendar Q1 2027. We entered into a clinical supply agreement with Novo Nordisk, and we now have an issued US patent for enobosarm with semaglutide with expiry in late 2044."

Industry Context

StockSavvy.ai notes that the pivot to pancreatic cancer addresses a significant unmet medical need, given the high lethality and increasing incidence of the disease, coupled with the challenge of acquired drug resistance. The company's focus on KRAS-mutant cancers aligns with a major area of research and development in oncology.

Stakeholder Impact

• Shareholders may see potential upside from the strategic pivot to a high-need oncology indication, but also face risks associated with the need for additional funding.
• Patients with KRAS-mutant pancreatic cancer resistant to daraxonrasib may benefit from a new treatment option if sabizabulin proves effective.
• The decision to halt inflammation research may impact the allocation of resources and focus for the company.

Next Steps

• Seek regulatory clarity from the FDA through a pre-IND meeting in calendar Q4 2026 for the sabizabulin pancreatic cancer indication.
• Pursue a Phase 2b clinical study to evaluate sabizabulin in patients with metastatic pancreatic cancer progression while receiving daraxonrasib.
• Conduct an interim analysis of the Phase 2b PLATEAU clinical trial for enobosarm in Q1 2027.
• Release final topline clinical data for the Phase 2b PLATEAU study in Q4 2027.

Key Dates

Recommendation

The strategic shift to pancreatic cancer is promising given the unmet need, and the enobosarm program remains on track. However, the reliance on future funding for the sabizabulin program and the inherent risks in clinical development warrant a cautious 'hold' rating until further clinical data and funding clarity emerge.

Keywords

sabizabulin, pancreatic cancer, KRAS, daraxonrasib, oncology, drug resistance, clinical trial, biopharmaceutical